Safety of Specifically Targeting Interleukin 13 With Tralokinumab in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-Blind, Placebo-Controlled Phase 3 and Phase 2 Trials. J of Skin 2021, 5 (1), s11. https://doi.org/10.25251/skin.5.supp.11.